<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The occurrence of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) has been reported after treatment with cytotoxic <z:chebi fb="0" ids="22333">alkylating agent</z:chebi>-based chemotherapy for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We report a patient with metastatic <z:mp ids='MP_0003579'>ovarian carcinoma</z:mp> treated with <z:chebi fb="2" ids="31355">carboplatin</z:chebi> and paclitaxel, who developed secondary <z:hpo ids='HP_0011009'>acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The overall survival of patients with stage III and IV <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> has increased in the past decade </plain></SENT>
<SENT sid="3" pm="."><plain>Monitoring of the long-term outcome of paclitaxel- and <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-based regimens is warranted, particularly with regard to monitoring the development of <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> and/or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence and outcome of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> in the setting of active <z:mp ids='MP_0003579'>ovarian carcinoma</z:mp> is reviewed </plain></SENT>
</text></document>